(VIANEWS) – Shares of Sorrento Therapeutics (NASDAQ: SRNE) dropped by a staggering 23.92% in 14 days from $2.09 to $1.59 at 10:46 EST on Monday, after five consecutive sessions in a row of losses. NASDAQ is rising 1.03% to $10,979.98, after four successive sessions in a row of losses.
Sorrento Therapeutics’s last close was $1.55, 81.1% below its 52-week high of $8.20.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc. is a commercial and clinical biopharmaceutical firm that develops treatments for neurodegenerative, autoimmune, viral, and cancer. The company operates in two segments: Sorrento Therapeutics, and Scilex. It offers cancer therapy by using its G-MAB antigen library and targeted delivery methods. These include antibody drug conjugate and chimeric antigen- receptor T cell therapy (CAR–T), and dimeric antigen receptor therapy T-cell treatment. The company’s current clinical programs include anti-CD38 CAR–T therapy to treat multiple myeloma and amyloidosis. It produces resiniferatoxin (a non-opioid TRPV1 antagonist neurotoxin) for treatment of late-stage cancers and osteoarthritis. ZTlido is a system that delivers lidocaine for postherpetic neuralgia. SEMDEXA is an injectable viscous jelly formulation that has been developed for treatment of sciatica. SP-103, an investigational topical lidocaine system, is currently in clinical development for chronic low back pain. SP-104, a low-dose, delayed-release formulation of naltrexone hydrochloride for the treatment fibromyalgia. SmartPharm Therapeutics Inc. has collaborated with it to create a gene-encoded vaccine against COVID-19. Celularity, Inc. is responsible for starting Phase I/II clinical studies, which included up to 94 patients suffering from COVID-19. Mount Sinai Health System will develop COVID-SHIELD, an anti-SARS treatment. Mayo Clinic was involved in Phase Ib pilot research using sofusa lymphatic drug transport technology to deliver Ipilimumab to patients with mela. It was established in San Diego in 2006.
Earnings Per Share
As for profitability, Sorrento Therapeutics has a trailing twelve months EPS of -1.3.
Return on Equity (TTM)
Sorrento Therapeutics’s ROE is -206.57.
Today’s last reported volume for Sorrento Therapeutics is 1054475 which is 88.43% below its average volume of 9121606.
Sorrento Therapeutics’s Sales
Sorrento Therapeutics’s sales growth is 29% for the present quarter and 85.1% for the next.
Sorrento Therapeutics’s Revenue
Year-on-year quarterly revenue growth grew by 29%, now sitting on 57.03M for the twelve trailing months.
Sorrento Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.26%, a negative 1.56%, and a positive 5.90%, respectively.
Sorrento Therapeutics’s highest amplitude of average volatility was 3.75% (last week), 6.88% (last month), and 5.90% (last quarter), respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Sorrento Therapeutics’s stock is considered to be overbought (>=80).
Sorrento Therapeutics’s Stock Yearly Top and Bottom Value
Sorrento Therapeutics’s stock is valued at $1.59 at 10:46 EST, way under its 52-week high of $8.20 and way above its 52-week low of $1.15.
Sorrento Therapeutics’s Moving Average
Sorrento Therapeutics’s value is way below its 50-day moving average of $2.28 and way under its 200-day moving average of $2.68.
More news about Sorrento Therapeutics (SRNE).